Baird lowered the firm’s price target on Jazz Pharmaceuticals (JAZZ) to $155 from $167 and keeps an Outperform rating on the shares. The firm updated its model following Q1 results where they were light on revenue but 2025 guidance is maintained.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JAZZ:
- Jazz Pharmaceuticals price target raised to $216 from $213 at BofA
- Jazz Pharmaceuticals price target lowered to $166 from $183 at Morgan Stanley
- Optimistic Growth Outlook for Jazz Pharmaceuticals Amid Strategic Product Focus and Pipeline Catalysts
- Positive Outlook for Jazz Pharmaceuticals: Buy Rating Affirmed Amid Strategic Moves and Upcoming Catalysts
- Jazz Pharmaceuticals: Buy Rating Affirmed Amid Growth Potential and Transformative Catalysts